Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 15;17(5):3665-3673.
doi: 10.62347/RKJN6285. eCollection 2025.

Transurethral holmium laser enucleation of prostate shows remarkable efficacy in treating benign prostatic hyperplasia

Feng-Rong He  1 , Guo-Deng Jian  1 , Ri-Zhao Tan  1 , Yi-Nuo Xu  1 , Bin Zheng  1
Affiliations

Transurethral holmium laser enucleation of prostate shows remarkable efficacy in treating benign prostatic hyperplasia

Feng-Rong He et al. Am J Transl Res. .

Abstract

Objective: To evaluate the effects of transurethral holmium laser enucleation of the prostate (HoLEP) in treating benign prostatic hyperplasia (BPH).

Methods: This retrospective study included 100 BPH patients who visited Foshan Fosun Chancheng Hospital from January 2022 to June 2023. Patients were divided into two groups: 50 treated with transurethral resection of the prostate (control group) and 50 with transurethral HoLEP (observation group). We compared clinical efficacy, surgical parameters, maximum urinary flow rate (Qmax), post-void residual volume (PRV), prostate-specific antigen (PSA), hemoglobin (Hb), interleukin-6 (IL-6), C-reactive protein (CRP), International Prostate Symptom Score (IPSS), quality of life (QOL), and complication rates.

Results: The observation group showed significantly reduced operative time, blood loss, catheterization duration, and hospitalization compared to the control group (all P<0.05). Postoperatively, Qmax was higher and PRV lower in the observation group (both P<0.05). PSA was lower, and Hb was higher in the observation group than those in the control group (both P<0.05). Both IL-6 and CRP levels increased post-surgery, but were significantly lower in the observation group (both P<0.05). The observation group also had better IPSS and QOL scores and a lower complication rate (16% vs. 56%, all P<0.05).

Conclusion: HoLEP is an effective treatment for BPH, offering advantages such as reduced surgical time, lower complication rates, improved urodynamics, and better patient outcomes in terms of symptoms and quality of life.

Keywords: Holmium laser enucleation of the prostate; benign prostatic hyperplasia; efficacy; transurethral resection of the prostate.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Comparison of serum inflammatory factors before and after surgery. A. Pre- and post-operative IL-6 levels in the two groups. B. Pre- and post-operative CRP levels in the two groups. Note: IL-6, interleukin-6; CRP, C-reactive protein. *P<0.05 vs. the level before surgery; #P<0.05 vs. the control group.
See this image and copyright information in PMC

References

    1. AbdelRazek M, Abolyosr A, Mhammed O, Fathi A, Talaat M, Hassan A. Prospective comparison of tadalafil 5 mg alone, silodosin 8 mg alone, and the combination of both in treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. World J Urol. 2022;40:2063–2070. - PMC - PubMed
    1. Ohara E, Aoki H, Arakawa Y, Kato A, Shibuya R, Ishidoya S. Basal cell carcinoma of the prostate diagnosed incidentally with holmium laser enucleation of the prostate: how can we detect prior to benign prostatic hyperplasia surgery? IJU Case Rep. 2021;4:204–206. - PMC - PubMed
    1. Kore RN. Management of urethral strictures and stenosis caused by the endo-urological treatment of benign prostatic hyperplasia-a single-center experience. Asian J Urol. 2023;10:137–143. - PMC - PubMed
    1. Bertolo R, Dalpiaz O, Bozzini G, Cipriani C, Vittori M, Alber T, Maiorino F, Carilli M, Zeder R, Iacovelli V, Antonucci M, Sandri M, Bove P. Thulium laser enucleation of prostate versus laparoscopic trans-vesical simple prostatectomy in the treatment of large benign prostatic hyperplasia: head-to-head comparison. Int Braz J Urol. 2022;48:328–335. - PMC - PubMed
    1. Abt D, Mullhaupt G, Hechelhammer L, Markart S, Gusewell S, Schmid HP, Mordasini L, Engeler DS. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-yr outcomes of a randomised, open-label, single-centre trial. Eur Urol. 2021;80:34–42. - PubMed

LinkOut - more resources